Page 1835 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 106 Haploidentical Hematopoietic Cell Transplantation 1632.e5

161. O’Donnell PV, Eapen M, Horowitz MM, et al: Comparable outcomes 178. Sun Y, Beohou E, Labopin M, et al: Unmanipulated haploidentical
with marrow or peripheral blood as stem cell sources for hematopoietic versus matched unrelated donor allogeneic stem cell transplantation in
cell transplantation from haploidentical donors after non-ablative con- adult patients with acute myelogenous leukemia in first remission: a
ditioning: a matched-pair analysis. Bone Marrow Transplant 51:2016, retrospective pair-matched comparative study of the Beijing approach
1599. with the EBMT database. Haematologica 101:e352, 2016.
162. O’Donnell P, Raj K, Pagliuca A: High fever occurring 4 to 5 days 179. Ciurea SO, Zhang MJ, Bacigalupo AA, et al: Haploidentical transplant
post-transplant of haploidentical bone marrow or peripheral blood stem with posttransplant cyclophosphamide vs matched unrelated donor
cells after reduced-intensity conditioning associated with the use of transplant for acute myeloid leukemia. Blood 126(8):1033–1040, 2015.
post-transplant cyclophosphamide as prophylaxis for graft-versus-host 180. Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al: Reduced-intensity
disease. Biol Blood Marrow Transplant 21(1):197–198, 2015. transplantation for lymphomas using haploidentical related donors vs
163. Abboud R, Keller J, Slade M, et al: Severe cytokine-release syndrome HLA-matched unrelated donors. Blood 127(7):938–947, 2016.
after T cell-replete peripheral blood haploidentical donor transplanta- 181. Luo Y, Xiao H, Lai X, et al: T-cell-replete haploidentical HSCT with
tion is associated with poor survival and anti-IL-6 therapy is safe and low-dose anti-T-lymphocyte globulin compared with matched sibling
well tolerated. Biol Blood Marrow Transplant 22:2016, 1851. HSCT and unrelated HSCT. Blood 124:2735, 2014.
164. Crocchiolo R, Bramanti S, Vai A, et al: Infections after T-replete 182. Wang Y, Liu QF, Xu LP, et al: Haploidentical vs identical-sibling
haploidentical transplantation and high-dose cyclophosphamide as transplant for AML in remission: a multicenter, prospective study.
graft-versus-host disease prophylaxis. Transpl Infect Dis 17:242, 2015. Blood 125(25):3956–3962, 2015.
165. Ruggeri A, Roth-Guepin G, Battipaglia G, et al: Incidence and risk 183. Di Stasi A, Milton DR, Poon LM, et al: Similar transplantation
factors for hemorrhagic cystitis in unmanipulated haploidentical outcomes for acute myeloid leukemia and myelodysplastic syndrome
transplant recipients. Transpl Infect Dis 17:822, 2015. patients with haploidentical versus 10/10 human leukocyte antigen-
166. Rimondo A, Crocchiolo R, El-Cheikh J, et al: The calcineurin inhibitor matched unrelated and related donors. Biol Blood Marrow Transplant
and the intensity of the conditioning regimen may affect the occurrence 20(12):1975–1981, 2014.
of polyomavirus-associated hemorrhagic cystitis after haploidentical 184. McCurdy SR, Kanakry CG, Kasamon YL, et al: Graft-versus-host
hematopoietic stem cell transplantation with post-transplant cyclophos- disease (GVHD) and survival outcomes after HLA-haploidentical
phamide. Bone Marrow Transplant 52:135, 2017. (Haplo) bone marrow transplant (BMT) compare favorably with
167. Leffell MS, Jones RJ, Gladstone DE: Donor HLA-specific Abs: to BMT matched related donor (MRD), and matched unrelated donor (MUD)
or not to BMT? Bone Marrow Transplant 50:751, 2015. BMT utilizing high-dose posttransplantation cyclophosphamide
168. Bramanti S, Nocco A, Mauro E, et al: Desensitization with plasma (PTCy). Blood 124:730, 2014.
exchange in a patient with human leukocyte antigen donor-specific 185. Bashey A, Zhang X, Jackson K, et al: Comparison of outcomes of
antibodies before T-cell–replete haploidentical transplantation. Transfu- hematopoietic cell transplants from T-replete haploidentical donors
sion 56(5):1096–1100, 2016. using post-transplantation cyclophosphamide with 10 of 10 HLA-A,
169. Kanakry JA, Kasamon YL, Bolanos-Meade J, et al: Absence of post- -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-
transplantation lymphoproliferative disorder after allogeneic blood or identical sibling donors: a multivariable analysis including disease risk
marrow transplantation using post-transplantation cyclophosphamide index. Biol Blood Marrow Transplant 22:125, 2016.
as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 186. Blaise D, Fürst S, Crocchiolo R, et al: Haploidentical T cell-replete
19(10):1514–1517, 2013. transplantation with post-transplantation cyclophosphamide for
170. Symons HJ, Mogri H, Kanakry JA, et al: Rarity of donor-derived patients in or above the sixth decade of age compared with allogeneic
malignancy after allogeneic BMT with high-dose post-transplantation hematopoietic stem cell transplantation from an human leukocyte
cyclophosphamide. Biol Blood Marrow Transplant 20(2 Suppl):S252, antigen-matched related or unrelated donor. Biol Blood Marrow Trans-
2014. plant 22:119, 2016.
171. Leventhal J, Abecassis M, Miller J, et al: Chimerism and tolerance 187. Ghosh N, Karmali R, Rocha V, et al: Reduced-intensity transplanta-
without GVHD or engraftment syndrome in HLA-mismatched com- tion for lymphomas using haploidentical related donors versus HLA-
bined kidney and hematopoietic stem cell transplantation. Sci Transl matched sibling donors: a Center for International Blood and Marrow
Med 4:124ra128, 2012. Transplant Research analysis. J Clin Oncol 34:3141, 2016.
172. Leventhal J, Abecassis M, Miller J, et al: Tolerance induction in HLA 188. Wang Y, Chang YJ, Xu LP, et al: Who is the best donor for a related
disparate living donor kidney transplantation by donor stem cell infu- HLA haplotype-mismatched transplant? Blood 124(6):843–850,
sion: durable chimerism predicts outcome. Transplantation 95:169, 2014.
2013. 189. Yoshihara S, Maruya E, Taniguchi K, et al: Risk and prevention of
173. Leventhal JR, Elliott MJ, Yolcu ES, et al: Immune reconstitution/ graft failure in patients with preexisting donor-specific HLA antibodies
immunocompetence in recipients of kidney plus hematopoietic stem/ undergoing unmanipulated haploidentical SCT. Bone Marrow Trans-
facilitating cell transplants. Transplantation 99(2):288–298, 2015. plant 47(4):508–515, 2012.
174. Ciurea SO, Mulanovich V, Saliba RM, et al: Improved early outcomes 190. Tang BL, Zhu XY, Zheng CC, et al: Successful early unmanipulated
using a T cell replete graft compared with T cell depleted haploidentical haploidentical transplantation with reduced-intensity conditioning
hematopoietic stem cell transplantation. Biol Blood Marrow Transplant for primary graft failure after cord blood transplantation in hemato-
18(12):1835–1844, 2012. logic malignancy patients. Bone Marrow Transplant 50(2):248–252,
174a. Ruggeri A, Sun Y, Labopin M, et al: Post-transplant cyclophosphamide 2015.
versus anti-thymocyte globulin as graft-versus-host disease prophylaxis 191. Rihani R, Lataifeh I, Halalsheh H, et al: Haploidentical stem cell
in haploidentical transplant. Haematologica 102(2):401–410, 2017. transplantation as a salvage therapy for cord blood engraftment failure
175. Ruggeri A, Labopin M, Sanz G, et al: Comparison of outcomes after in a patient with Fanconi anemia. Pediatr Blood Cancer 55(3):580–582,
unrelated cord blood and unmanipulated haploidentical stem cell trans- 2010.
plantation in adults with acute leukemia. Leukemia 29(9):1891–1900, 192. Aboul Nour H, Patil N, Chewning JH, et al: Safety of repeated
2015. un-manipulated peripheral blood stem cell haploidentical transplant
176. Brunstein CG, Fuchs EJ, Carter SL, et al: Alternative donor trans- for graft failure. Bone Marrow Transplant 52:157, 2017.
plantation after reduced intensity conditioning: results of parallel 193. Epperla N, Pasquini M, Pierce K, et al: Salvage haploidentical
phase 2 trials using partially HLA-mismatched related bone marrow or hematopoietic cell transplantation for graft rejection following a prior
unrelated umbilical cord blood grafts. Blood 118:282, 2011. haploidentical allograft. Bone Marrow Transplant 52:147, 2017.
177. Eapen M, O’Donnell P, Brunstein CG, et al: Mismatched related and 194. Duran-Struuck R, Matar A, Crepeau R, et al: Lack of antidonor
unrelated donors for allogeneic hematopoietic cell transplantation for alloantibody does not indicate lack of immune sensitization: studies of
adults with hematologic malignancies. Biol Blood Marrow Transplant graft loss in a haploidentical hematopoietic cell transplantation swine
20(10):1485–1492, 2014. model. Biol Blood Marrow Transplant 18(11):1629–1637, 2012.